JNK

Tanzisertib (CC-930) (CC-930) is a potent inhibitor of JNK1/2/3 with IC50s of 61/7/6 nM, respectively, with potential antifibrotic activity.

Mefloquine hydrochloride (Mefloquin hydrochloride) is a quinoline derivative used for the prevention and therapy of P. falciparum malaria.

Metacetamol, a non-toxic acetaminophen derivative, is an OTC analgesic/antipyretic and synthesis intermediate.

Urolithin B is one of the gut microbial metabolites of ellagitannins and is found in diverse plant foods, including pomegranates, berries, walnuts, tropical

SU3327 (halicin) is a potent, selective and substrate-competitive inhibitor of JNK(IC50 of 0.7 μM).

NBDHEX is a potent inhibitor of glutathione S-transferase P1-1 (GSTP1-1).

Chloramphenicol (Chloromycetin) is a broad-spectrum antibiotic that inhibits the biosynthesis of bacterial proteins. Cost-effective and quality-assured.

A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;

JNK-IN-12 (compound P2) is a mitochondrial-targeted JNK inhibitor with an IC50 value of 66.3 nM, comprising a mitochondrial-specific cell-penetrating peptide

MAP4K4-IN-6 (Compound 15f) is a MAP4K4 inhibitor with an IC50 of 80 nM. It reduces the phosphorylation of c-Jun and exhibits neuroprotective effects. Additionally, MAP4K4-IN-6 enhances the vitality of motor neurons and can be utilized in the study of amyotrophic lateral sclerosis (ALS).

JTP10-△-TATi TFA is a selective inhibitor of JNK2 peptide (IC50: 92 nM), exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.

PROTAC JNK1-targeted-1 (PA2) is a JNK1 PROTAC degrader with a DC50 of 10 nM. It effectively reduces fibronectin levels and is useful in lung fibrosis research. [Pink: JNK1 inhibitor; Black: linker; Blue: CRBN Ligand]

D-JNKI-1 (AM-111) is a highly effective and cell-permeable peptide inhibitor.

N-Butyl α-D-fructofuranoside, extracted from the root barks of Ulmus davidiana var.

L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK, it has been shown to effectively inhibit JNK activity in in vivo studies.

JNK2-IN-1 (Compound J27), a selective JNK2 inhibitor with a dissociation constant (Kd) of 79.2 µM, exhibits anti-inflammatory effects by attenuating TNF-α and

JNK3 inhibitor-8: potent, selective, oral, BBB-penetrating, IC50: JNK3=21 nM, JNK2=2203 nM, JNK1>10,000 nM; potential in Alzheimer's research.

"JNK-1-IN-2 (Compound c6) is a potent inhibitor of JNK-1 with an IC50 of 33.5 nM, and also exhibits inhibitory effects on JNK-2 and JNK-3 with IC50 values of

AS601245.2TFA (345987-15-7 free base) (AS601245.2TFA) is a cell-permeable Inhibitor of JNK (IC50s of 150, 220, and 70 nM for hJNK1, hJNK2, and hJNK3,

JNK-IN-14 is a potent inhibitor of JNK with IC50 values of 1.81 nM for JNK1, 12.7 nM for JNK2, and 10.5 nM for JNK3.

IQ-1S is an inhibitor of NF-κB/activating protein 1 (AP-1) with an IC50 of 1.8 μM. It exhibits high binding affinity to all three JNKs, with Kd values for JNK3, JNK2, and JNK1 being 87 nM, 360 nM, and 390 nM, respectively.

OVA-E1 peptide TFA activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes.

Peptide based on JIP-1(153-163) inhibits JNK with micromolar affinity; barely affects p38, ERK.

BSO-07 is a ROS/JNK activator that exhibits potent anti-cancer properties, demonstrated by an IC50 of 24.81 μM in human breast cancer (BC) cells. The mechanism of action for BSO-07 involves JNK activation and the promotion of increased ROS levels, which lead to the induction of apoptosis (Apoptosis) and tumorigenic apoptosis. This includes enhanced expression of apoptosis-related proteins such as PARP, Bax, phosphorylated p53, ATF4, and CHOP, along with a reduction in the levels of anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL, and Survivin). BSO-07 holds promise for research in the field of breast cancer.

Potent, oral JNK3 inhibitor-7 crosses blood-brain barrier, IC50: 53 nM (JNK3), offers neuroprotection, potential in AD research.

Salicortin, a phenolic glycoside from Populus and Salix, has anti-adipogenic, anti-amnesic, and immune effects.

OVA-E1 peptide, as SIINFEKL variant, triggers similar p38/JNK activation in mutant and normal thymocytes.

JTP10-△-R9 TFA is a selective inhibitor of JNK2 peptide (IC50: 89 nM), exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.

Fasudil (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK.

Vacquinol-1 is an MKK4 activator, which rapidly and selectively induces glioma cell death.

JNK-1-IN-3 (Compound 9e) downregulates JNK1 and phosphorylated JNK1, reduces c-Jun and c-Fos expression in tumours, and restores p53 activity.

JNK-IN-18 (compound 23b) is a potent inhibitor of JNK1, boasting an IC50 of 2 nM. It demonstrates superior efficacy when compared to its IC50 values of 125 nM for JNK2 and 98 nM for BRAF(V600E).

A unique collection of 365 compounds targeting MAPK signaling for drug discovery in MAPK related diseases;

D-JBD19 is a non-permeable peptide with neuroprotective effects.

SET-171 is a JNK (c-Jun N-terminal kinase) inhibitor that exhibits significant anticancer activity by suppressing the expression of hepatic pyruvate kinase (PKL) and offers potential in regulating lipid metabolism. In antitumor studies, SET-171 shows notable cytotoxicity against human liver cancer cell lines HepG2 and Huh7, with IC50 values of 8.82 μM and 2.97 μM, respectively. Additionally, in research related to non-alcoholic fatty liver disease (NAFLD), SET-171 significantly reduces triglyceride (TAG) levels and inhibits the expression of proteins associated with steatosis. This compound holds promise for hepatocellular carcinoma (HCC) and NAFLD research.

Ezatiostat (TER199(free base)) is a tripeptide analog of glutathione that can selectively inhibit GSTP1-1 catalytic activity.

Mitogen-activated protein kinase 8 (MAPK8), also known as JNK1, is a member of the MAP kinase family.

D-JNKI-1 acetate (AM-111 acetate) is a highly potent and cell-permeable peptide inhibitor of JNK.

IMM-H007 is a novel lipid-lowering agent, increasing abca1 protein expression

AS601245 is an inhibitor of the c-Jun NH2-terminal kinase (JNK), with neuroprotective properties.

JNK Inhibitor VIII (TCS JNK 6o) is an ATP-competitive selective inhibitor of c-Jun N-terminal kinase (JNK)(IC50 values of 45 nM and 160 nM for JNK-1 and -2,

Taurochenodeoxycholic Acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid.

DB07268 is a potent and selective JNK1 inhibitor.

SP600125 (JNK Inhibitor II) is a JNK inhibitor that inhibits JNK1, JNK2, and JNK3 (IC50=40/40/90 nM) with oral potency, reversibility, and ATP-competitive

BI-78D3, a competitive JNK inhibitor. IC50 of BI-78D3 is 280 nM that displays > 100 fold selectivity over p38α, and have no activity at mTOR and PI-3K.

Anisomycin (NSC-76712), an antibiotic from Streptomyces, blocks protein/DNA synthesis by targeting peptidyl transferase/80S ribosomes.

Loureirin B suppresses fibrosis by modulating MMPs/TIMPs, hindering fibroblast growth, and targeting TGF-β1/Smad2/3 pathway.

Tomatidine hydrochloride (Tomatidine HCl) is a steriodal alkaloid structurally similar to Cyclopamine but does not inhibit hedgehog pathway.

Actein stimulates bone formation, counters osteoporosis and oxidative damage, and may treat lipid disorders and cancer, inhibiting breast cancer cell growth.

Polyphyllin D induces apoptosis via the mitochondrial apoptotic pathway as evidenced by decreased Bcl-2 expression levels, disruption of MMP and increased Bax,

Ro 31-8220 Mesylate (Bisindolylmaleimide IX mesylate) is a pan-PKC inhibitor, and also shows potent inhibition against MSK1, MAPKAP-K1b, S6K1, and GSK3β.

Guggulsterone (Guggulsterone E&Z) E&Z is a 3-hydroxy steroid. It has a role as an androgen.

JNK-IN-7 (JNK inhibitor) is a selective JNK1/2/3 inhibitor (IC50: 1.54/1.99/0.75 nM).

CC-401 Hydrochloride (CC401 HCl) is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with antineoplastic activity.

JNK peptide inhibitor. Mimics JIP-1 residues 153-163. Micromolar affinity, little effect on p38, ERK.

Ro 31-8220: potent PKC inhibitor (IC50: 5-27 nM). Affects MAPKAP-K1b, MSK1, S6K1, GSK3β (IC50: 3-38 nM), not MKK3/4/6/7.

Bentamapimod (AS 602801) is a novel, orally active inhibitor of JNK.

Astragaloside IV suppresses ERK1/2, JNK, MMP-2/9 in breast cancer; inhibits adenovirus and protects cardiovascular, immune, digestive, nervous systems.

JNK-IN-8 (JNK Inhibitor XVI) is an irreversible JNK1/2/4 inhibitor (IC50: 4.7/18.7/1 nM).

Epieriocalyxin A can suppress Caco-2 colon cancer cell growth. It could be a potential drug for colon cancer therapy in the future.

Juglanin is a JNK activator. Juglanin with inflammation and anti-tumor activities. It can induce apoptosis and autophagy on human breast cancer cells.

TRi-1 irreversibly inhibits TXNRD1 (IC50: 12 nM) with low mitochondrial toxicity for cancer treatment.

1.

Indirubin-3′-oxime is an effective inhibitor of cyclin-dependent protein kinases, and may play an obligate role in neuronal apoptosis in Alzheimer's disease.

IQ-1S free acid (IQ-1S) is an effective and specific c-Jun N-Terminal Kinase Inhibitor. IQ-1S inhibits murine delayed-type hypersensitivity.

Sodium taurochenodeoxycholate: induces apoptosis, anti-inflammatory, boosts insulin, stimulates α2-cells, increases [Ca(2+)](c).

Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.

CC-90001 is an orally administered c-Jun N-terminal kinase (JNK) inhibitor with bias for JNK1 over JNK2.

Phytolaccaceae has anti-tumor activity, the mechanism may be related to the capacity of Esculentoside H for TNF release.

TCS JNK 5a (SC202671) is an effective, specific inhibitor of JNK3(pIC50= 6.7), JNK2(pIC50=6.5).

Ginsenoside Re (Ginsenoside B2) may have properties that inhibit or prevent the growth of tumors.